Related Experiment Video
Updated: Jun 1, 2026

Intracerebroventricular Treatment with Resiniferatoxin and Pain Tests in Mice
Published on: September 2, 2020
Analgesic potential of TRPV3 antagonists
Regina M Reilly1, Philip R Kym
1Nueroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064-6125, USA.
Abstract:
The vanilloid subfamily of transient receptor potential (TRPV) ion channels serves critical functions in sensory signaling in specialized cells and intact organisms ranging from yeast to primates. As thermosensors, chemosensors, and/or mechanosensors, these channels monitor the local environment and integrate and respond to multiple stimuli distinctively. More than a decade of research on the founding member of the subclass, TRPV1, has led to advancement of multiple antagonists into the clinic for the treatment of chronic pain. In recent years the comprehensive knowledge accessed through these studies has been applied to enhance understanding of other TRPV isoforms and, in particular, to determine whether they, too, represent promising targets for drug discovery. This review focuses on emerging data that define a role for TRPV3 in transducing signals in pain pathways and identify antagonists that demonstrate efficacy in relevant preclinical behavioral models.
Related Concept Videos
Analgesia and Pain Management
Thermosensation
Local Anesthetics: Differential Sensitivity of Nerve Fibers
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Acute Inflammation III: Local and Systemic Effects
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
